Table 1.

Baseline and 6-month follow-up characteristics.

	Baseline			6-Month Follow-Up
	N	Mean	SD	N	Mean	SD	p
SLTS-7 composite (Items 2–7)	121	39.5	10.2	121	41.9	12.0	0.04
Satisfaction with
1.Life as a whole	121	6.8	2.0	121	7.1	1.9	0.100
2.Physical health	121	5.1	2.2	121	5.9	2.0	<0.001
3.Psychological health	121	6.9	2.2	121	7.0	2.3	0.624
4.Social relations	121	7.2	2.2	121	7.2	2.2	0.675
5.Leisure	121	6.8	2.2	121	7.1	2.1	0.168
6.PD treatment	121	7.0	2.2	121	7.7	2.0	0.003
7.Expectations met	121	6.5	2.2	121	7.1	2.5	0.035
Psycho-social well-being domain (Items 3–5)	121	20.9	5.7	121	21.3	6.1	0.224
Treatment domain (Items 6–7)	121	13.6	4.2	121	14.8	4.2	0.007
PDQ-8 Summary Index	121	31.9	15.7	120	24.4	16.1	<0.001
EQ-5D-3L TTO *	119	0.8	0.2	120	0.8	0.2	0.001
EQ-VAS	118	57.2	19.6	119	64.4	19.1	0.001
NMSS total	121	56.3	31.1	120	39.1	25.2	<0.001
HADS total	120	10.5	6.3	121	8.9	6.2	0.003
UPDRS total	120	24.0	10.7	113	18.0	9.2	<0.001
Part I: cognition, behavior, mood	121	1.9	1.7	121	1.6	1.3	0.281
Part II: activities of daily living	121	12.5	5.9	121	9.7	5.4	<0.001
Part III: motor examination	120	24.0	10.7	113	18.0	9.2	<0.001
Part IV: motor complications	121	6.9	3.5	121	3.7	3.2	<0.001
LEDD total	121	1125.4	529.6	121	536.6	296.9	<0.001

Significant results are highlighted in bold font. Within group changes from baseline to 6-month follow-up were analyzed with Wilcoxon signed-rank tests. Post-hoc, we explored the SLTS-7 items and composite scores. Abbreviations: EQ-5D-3L = European Quality of Life Questionnaire with 5 Dimensions and 3 Levels; HADS = Hospital Anxiety and Depression Scale; LEDD = Levodopa Equivalent Daily Dose; NMSS = Non-Motor Symptom Scale; N = Number; PDQ-8 = eight-item Parkinson’s Disease Questionnaire; SD = Standard Deviation; SLTS-7 = Satisfaction with Life and Treatment Scale-7; TTO = Time-Trade-Off; UPDRS = Unified Parkinson’s Disease Rating Scale; VAS = Visual Analogue Scale. * Adapted to Country according to EuroQol.